Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis

European Journal of Pharmacology

Volumn 686, Issue 1-3, 2012, Pages 81-89

  Kalaska, Bartlomiej ^a   Sokolowska, Emilia ^a   Kaminski, Kamil ^b   Szczubialka, Krzysztof ^b   Kramkowski, Karol ^a   Mogielnicki, Andrzej ^a   Nowakowska, Maria ^b   Buczko, Wlodzimierz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Coagulation; Heparin; Modified dextran; Protamine; Thrombosis

Indexed keywords

AMMONIUM CHLORIDE; DEXTRAN DERIVATIVE; FERROUS CHLORIDE; GLYCIDYLTRIMETHYLAMMONIUM; HEMOGLOBIN; HEPARIN; POLYMER; PROTAMINE; PROTAMINE SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; ELECTROSTIMULATION; ERYTHROCYTE COUNT; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLEEDING TIME; BLOOD COAGULATION; CHLORIDES; DEXTRANS; DISEASE MODELS, ANIMAL; FERRIC COMPOUNDS; HEPARIN; HEPARIN ANTAGONISTS; MALE; MICE; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; PROTAMINES; RATS; RATS, WISTAR; THROMBOSIS;

EID: 84861630892     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.04.037     Document Type: Article

References (54)

1. E.M. Antman, D.T. Anbe, P.W. Armstrong, E.R. Bates, L.A. Green, M. Hand, J.S. Hochman, H.M. Krumholz, F.G. Kushner, G.A. Lamas, C.J. Mullany, J.P. Ornato, D.L. Pearle, M.A. Sloan, S.C. Smith, J.S. Alpert, J.L. Anderson, D.P. Faxon, V. Fuster, R.J. Gibbons, G. Gregoratos, J.L. Halperin, L.F. Hiratzka, S.A. Hunt, A.K. Jacobs, and J.P. Ornato ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) J. Am. Coll. Cardiol. 44 2004 E1 E211
2. T. Baglin, T.W. Barrowcliffe, A. Cohen, and M. Greaves Guidelines on the use and monitoring of heparin Br. J. Haematol. 133 2006 19 34
3. A. Belboul, and N. al-Khaja The effect of protamine on the epicardial microflow and the graft flow in open-heart surgery Perfusion. 12 1997 99 106
4. A. Bernabei, N. Gikakis, T.E. Maione, M.A. Kowalska, Z. Yan, and S. Niewiarowski Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass J. Thorac. Cardiovasc. Surg. 109 1995 765 771
5. A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, D.M. Okamoto, S.J. Schwab, and D.A. Goodkin The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin New Engl. J. Med. 339 1998 584 590
6. D. Bolliger, F. Szlam, M. Azran, K. Koyama, J.H. Levy, R.J. Molinaro, and K.A. Tanaka The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentration Anesth. Analg. 111 2010 601 608
7. E. Braunwald, E.M. Antman, J.W. Beasley, R.M. Califf, M.D. Cheitlin, J.S. Hochman, R.H. Jones, D. Kereiakes, J. Kupersmith, T.N. Levin, C.J. Pepine, J.W. Schaeffer, E.E. Smith, D.E. Steward, P. Theroux, R.J. Gibbons, J.S. Alpert, D.P. Faxon, V. Fuster, G. Gregoratos, L.F. Hiratzka, A.K. Jacobs, and S.C. Smith ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol. 40 2002 1366 1374
8. H.R. Buller, G. Agnelli, R.D. Hull, T.M. Hyers, M.H. Prins, and G.E. Raskob Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 401S 428S
9. Y. Byun, V.K. Singh, and V.C. Yang Low molecular weight protamine: a potential nontoxic heparin antagonist Thromb Res. 94 1999 53 61
10. D.C. Cardinal, and R.J. Flower The electronic aggregometer: a novel device for assessing platelet behavior in blood J Pharmacol. Methods 3 1980 135 158
11. Y.Q. Chu, L.J. Cai, D.C. Jiang, D. Jia, S.Y. Yan, and Y.Q. Wang Allergic shock and death associated with protamine administration in a diabetic patient Clin. Ther. 32 2010 1729 1732
12. A.J. Chu, Z.G. Wang, M. Raicu, S. Beydoun, and N. Ramos Protamine inhibits tissue factor-initiated extrinsic coagulation Br. J. Haematol. 115 2001 392 399
13. J.J. Cook, S. Niewiarowski, Z. Yan, L. Schaffer, W. Lu, G.J. Stewart, D.M. Mosser, J.A. Myers, and T.E. Maione Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes Circulation 85 1992 1102 1109
14. C. Crawford Acta Chir. Scand. 79 1937 407 426
15. W. Cullmann, N. Müller, T.B. Lie, R.G. Kladetzky, and P. Jürgens Coagulation parameters and heparin levels in open-heart surgery Res. Exp. Med. 177 1980 111 117
16. G.J. Dehmer, R.A. Lange, D.A. Tate, M. Pirwitz, W. Daniel, M. Fisher, and E.M. Bonnem Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans Circulation 94 1996 347 352
17. D.E. Eslin, C. Zhang, K.J. Samuels, L. Rauova, L. Zhai, S. Niewiarowski, D.B. Cines, M. Poncz, and M.A. Kowalska Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin Blood 15 2004 3173 3180
18. W.H. Geerts, G.F. Pineo, J.A. Heit, D. Bergqvist, M.R. Lassen, C.W. Colwell, and J.G. Ray Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 338S 400S
19. A.R. Giles Guidelines for the use of animals in biomedical research Thromb. Haemost. 58 1987 1078 1084
20. S. Guarini A highly reproducible model of arterial thrombosis in rats J. Pharmacol. Toxicol. Methods 35 1996 101 105
21. J. Hirsh, T.E. Warkentin, R. Raschke, C. Granger, E.M. Ohman, and J.E. Dalen Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety Chest 114 1998 489S 510S
22. C.L. Holland, A.K. Singh, P.R.B. McMaster, and W. Fang Adverse reactions to protamine sulfate following cardiac surgery Clin. Cardiol. 7 1984 157 162
23. J.C. Horrow Protamine: a review of its toxicity Anesth. Analg. 64 1985 358 361
24. V.V. Kakkar, E.S. Field, A.N. Nicolaides, and P.T. Flute Low doses of heparin in prevention of deep-vein thrombosis Lancet 25 1971 669 671
25. M. Kaminska, A. Mogielnicki, A. Stankiewicz, K. Kramkowski, T. Domaniewski, W. Buczko, and E. Chabielska Angiotensin II via AT1 receptor accelerates arterial thrombosis renovascular hypertensive rats J. Physiol. Pharmacol. 56 2005 571 585
26. K. Kaminski, M. Plonka, J. Ciejka, K. Szczubialka, M. Nowakowska, B. Lorkowska, R. Korbut, and R. Lach Cationic derivatives of dextran and hydroxypropylcellulose as novel potential heparin antagonists J. Med. Chem. 54 2011 6586 6596
27. K. Kaminski, K. Szczubialka, K. Zazakowny, R. Lach, and M. Nowakowska Chitosan derivatives as novel potential heparin reversal agents J. Med. Chem. 53 2010 4141 4147
28. K. Kaminski, K. Zazakowny, K. Szczubialka, and M. Nowakowska pH-sensitive genipin-cross-linked chitosan microspheres for heparin removal Biomacromolecules. 9 2008 3127 3132
29. A. Karewicz, K. Zasada, K. Szczubialka, S. Zapotoczny, R. Lach, and M. Nowakowska Smart alginate-hydroxypropylcellulose microbeads for controlled release of heparin Int. J. Pharm. 385 2010 163 169
30. J.G. Kelton, J.W. Smith, T.E. Warkentin, C.P. Hayward, G.A. Denomme, and P. Horsewood Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4 Blood 83 1994 3232 3239
31. M. Kikura, M.K. Lee, and J.H. Levy Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass Anesth. Analg. 1996 223 227
32. K. Kramkowski, A. Mogielnicki, A. Leszczynska, and W. Buczko Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats J. Physiol. Pharmacol. 61 2010 317 324
33. M.N. Levine, G. Raskob, R.J. Beyth, C. Kearon, and S. Schulman Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 287S 310S
34. J.H. Levy, J.G. Cormack, and A. Morales Heparin neutralization by recombinant platelet factor 4 and protamine Anesth. Analg. 1995 35 37
35. J.D. Lewis, Y. Song, M.E. De Jong, S.M. Bagha, and J. Ausio A walk though vertebrate and invertebrate protamines Chromosoma 111 2003 473 482
36. B. Lindblad Protamine sulphate: a review of its effects: hypersensitivity and toxicity Eur J Vasc Surg. 3 1989 195 201
37. K.E. McLaughlin, and J. Dunning In patients post-cardiac surgery, do high doses of protamine cause increased bleeding? Interact. Cardiovasc. Thorac. Surg. 2 2003 424 426
38. J. McLean The thromboplastic action of cephalin Am. J. Physiol. 41 1916 250 257
39. S. Metz, and J.C. Horrow Protamine and newer heparin antagonists R.K. Stoelting, Pharmacology and Physiology in Anesthetic Practice vol 1 1994 JB Lippincott Philadelphia, Pa 1 15 3
40. T.A. Mixon, and G.J. Dehmer Recombinant platelet factor 4 for heparin neutralization Semin. Thromb. Hemost. 30 2004 369 377
41. T. Mochizuki, P.J. Olson, F. Szlam, J.G. Ramsay, and J.H. Levy Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass Anesth. Analg. 87 1998 781 785
42. A. Mogielnicki, K. Kramkowski, L. Pietrzak, and W. Buczko N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats J. Physiol. Pharmacol. 58 2007 515 527
43. D.R. Mungall, D. Anbe, P.L. Forrester, T. Luoma, R. Genovese, J. Mahan, S. LeBlanc, and J.B. Penney A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram-directed heparin therapy Clin. Pharmacol. Ther. 55 1994 591 596
44. H.J. Ng, and M.A. Crowther New anti-thrombotic agents: emphasis on hemorrhagic complications and their management Semin. Hematol. 43 2006 S77 S83
45. B.P. Schick, D. Maslow, A. Moshinski, and J.D. San Antonio Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo Blood 2004 1356 1363
46. W.A. Schumacher, C.L. Heran, S. Youssef, J.R. Megill, I. Michel, and S.K. Durham Comparison of a thromboxane receptor antagonist andaspirin in experimental arterial thrombosis Haemostasis 23 1993 219 228
47. P.J. Silver, R. Broughton, J. Bouthillier, T.A. Quinn, A.M. Wallace, and R.E. Weishaar Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis Thromb. Res. 91 1998 143 150
48. M. Stafford-Smith, E.A. Lefrak, A.G. Qazi, I. Welsby, L. Barber, A. Hoeft, A. Dorenbaum, J. Mathias, J.J. Rochon, and M.F. Newman Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass Anesthesiology 2005 229 240
49. G.P. Visentin, S.E. Ford, J.P. Scott, and R.H. Aster Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells J Clin Invest. 93 1994 81 88
50. Wakefield, T.W., Stanley, J.C., Andrews, P.C., 1996. Peptides for heparin and low molecular weight heparin anticoagulation reversal. United States Patent. 5, 534-619.
51. X. Wang, P.L. Smith, M.Y. Hsu, M.L. Ogletree, and W.A. Schumacher Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor J. Thromb. Haemost. 4 2006 403 410
52. J.M. Weiler, M.A. Gellhaus, J.G. Carter, R.L. Meng, P.M. Benson, R.A. Hottel, K.B. Schillig, A.B. Vegh, and W.R. Clarke A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery J. Allergy Clin. Immunol. 85 1990 713 719
53. I.J. Welsby, and M. Stafford-Smith Protamine contributes to myocardial ischemia Anesthesiology 103 2005 669 670
54. M. Wojewodzka-Zelezniakowicz, E. Chabielska, A. Mogielnicki, K. Kramkowski, A. Karp, A. Opadczuk, T. Domaniewski, M. Malinowska- Zaprzałka, and W. Buczko Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats J. Physiol. Pharmacol. 57 2006 231 245